Relief Announces Resignation of Thomaz Burckhardt as Member of the Board of Directors

Rhea-AI Summary

Relief Therapeutics Holding AG announced the immediate resignation of board member Thomaz Burckhardt, who is stepping down to focus on other professional interests. Chairman Raghuram Selvaraju expressed gratitude for Burckhardt's contributions. The company is seeking candidates to fill the vacancy with individuals who have substantial experience in life sciences and healthcare. Relief continues to prioritize its clinical-stage programs, notably RLF-100^TM, currently being tested for respiratory issues related to COVID-19.

Positive

• Relief is actively searching for a new board member with relevant life sciences experience, which may enhance governance and strategic focus.
• The ongoing clinical trials for RLF-100^TM could lead to significant advancements in respiratory treatments, thus potentially increasing market value.

Negative

• The resignation of a board member could raise concerns about continuity and leadership stability during a critical period of clinical trials.

GENEVA, SWITZERLAND / ACCESSWIRE / February 9, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF) ("Relief" or the "Company") announces the resignation, effective immediately, of Board of Directors member Thomaz Burckhardt. Mr. Burckhardt has resigned to focus his time and efforts on other professional duties and interests.

Raghuram (Ram) Selvaraju, Chairman of the Board of Relief, commented: "The Board of Directors and I would like to warmly thank Thomaz for his many contributions to the Company over the past years. We wish him well in his future endeavors."

Relief will evaluate potential candidates to serve on the Board of Directors who have substantial life sciences/healthcare experience with respect to appointing a new independent director to fill the current vacancy. The Company will continue to assess opportunities to expand both the Board and Executive Management team in order to optimize Relief's ability to execute on its business strategy going forward.

###

ABOUT RELIEF

Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate RLF-100^TM (aviptadil) is being investigated in two placebo-controlled U.S. late-stage clinical trials in respiratory deficiency due to COVID-19. Relief holds a patent issued in the United States and various other countries covering potential formulations of RLF-100^TM.

RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF.

www.relieftherapeutics.com

Follow us on LinkedIn

CONTACT: RELIEF THERAPEUTICS Holding AG Raghuram (Ram) Selvaraju, Ph.D., MBA Chairman of the Board Mail: contact@relieftherapeutics.com

FOR MEDIA/INVESTOR INQUIRIES: MC Services AG Anne Hennecke / Brittney Sojeva Tel.: +49 (0) 211-529-252-14 Mail: relief@mc-services.eu

Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG and its business. The results reported herein may or may not be indicative of the results of future and larger clinical trials for RLF-100(TM) for the treatment of respiratory illnesses. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and do not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

SOURCE: Relief Therapeutics Holdings AG

View source version on accesswire.com:
https://www.accesswire.com/628584/Relief-Announces-Resignation-of-Thomaz-Burckhardt-as-Member-of-the-Board-of-Directors

FAQ

Why did Thomaz Burckhardt resign from Relief Therapeutics?

Thomaz Burckhardt resigned to focus on other professional duties and interests.

What is the impact of the board resignation on Relief Therapeutics?

The resignation may cause concerns about leadership continuity, especially as the company seeks a candidate with relevant expertise.

What is Relief Therapeutics focusing on after the board resignation?

Relief Therapeutics is focusing on appointing a new board member and continuing its clinical-stage programs, particularly for its lead drug candidate RLF-100^TM.

What is RLF-100^TM and its significance to Relief Therapeutics?

RLF-100^TM is Relief's lead drug candidate being tested in late-stage clinical trials for respiratory deficiencies related to COVID-19.